Prediction of the Fatal Acute Complications of Myocardial Infarction via Machine Learning Algorithms
Reza Ghafari1, Amir Sorayaie Azar2, Ali Ghafari3,4
1Pharmacy Faculty, Urmia University of Medical Sciences, Urmia, Iran.
The Journal of Tehran Heart Center
|April 29, 2024
Summary
Machine learning models can predict fatal myocardial infarction (MI) complications within 72 hours of hospital admission. The XGBoost model showed high accuracy in identifying patients at risk, with cardiogenic shock being a key predictor.
Area of Science:
- Artificial Intelligence
- Data Science
- Cardiology
Background:
- Myocardial infarction (MI) is a leading cause of mortality, especially within the first year post-event.
- Early identification of patients at high risk of fatal complications is crucial for timely intervention.
- Machine learning (ML) offers powerful tools for analyzing complex health data to predict outcomes.
Purpose of the Study:
- To develop and evaluate a machine learning model for predicting fatal complications of MI within the initial 72 hours of hospital admission.
- To identify key clinical features that contribute to the prediction of adverse outcomes in MI patients.
Main Methods:
- Utilized a database of MI patient demographics and clinical records, classifying outcomes as deceased or alive.
- Applied Recursive Feature Elimination (RFE) for feature selection, reducing the dataset to 50 key features.
- Evaluated four ML algorithms (logistic regression, SVM, random forest, XGBoost) using eight performance metrics.
Main Results:
- The study included 1699 MI patients, with 15.94% experiencing fatal complications.
- The Extreme Gradient Boosting (XGBoost) model demonstrated superior performance, achieving high accuracy (91.47%) and F1-score (95.14%).
- Cardiogenic shock was identified as the most significant predictor of fatal complications in the XGBoost model.
Conclusions:
- XGBoost algorithms show significant promise as a predictive tool for fatal complications following myocardial infarction.
- This ML approach can aid clinicians in risk stratification and timely management of high-risk MI patients.


